OA12915A - Vaccine for respiratory and reproductive system infections in cattle. - Google Patents
Vaccine for respiratory and reproductive system infections in cattle. Download PDFInfo
- Publication number
- OA12915A OA12915A OA1200500058A OA1200500058A OA12915A OA 12915 A OA12915 A OA 12915A OA 1200500058 A OA1200500058 A OA 1200500058A OA 1200500058 A OA1200500058 A OA 1200500058A OA 12915 A OA12915 A OA 12915A
- Authority
- OA
- OAPI
- Prior art keywords
- bvdv
- leptospira
- virus
- vaccine
- type
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 115
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 65
- 241000283690 Bos taurus Species 0.000 title claims description 200
- 230000000241 respiratory effect Effects 0.000 title description 6
- 210000002345 respiratory system Anatomy 0.000 title description 6
- 210000004994 reproductive system Anatomy 0.000 title description 3
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims abstract description 216
- 241000589902 Leptospira Species 0.000 claims abstract description 42
- 241001465754 Metazoa Species 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 208000035475 disorder Diseases 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims description 86
- 239000000203 mixture Substances 0.000 claims description 45
- 239000002671 adjuvant Substances 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 230000002163 immunogen Effects 0.000 claims description 22
- 206010000210 abortion Diseases 0.000 claims description 21
- 231100000176 abortion Toxicity 0.000 claims description 20
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 claims description 18
- 241000589927 Leptospira borgpetersenii Species 0.000 claims description 16
- 244000309466 calf Species 0.000 claims description 16
- 230000000120 cytopathologic effect Effects 0.000 claims description 15
- 241000589876 Campylobacter Species 0.000 claims description 12
- 241000711895 Bovine orthopneumovirus Species 0.000 claims description 11
- 241000178947 Leptospira interrogans serovar Pomona Species 0.000 claims description 11
- 241001518154 Leptospira kirschneri serovar Grippotyphosa Species 0.000 claims description 10
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241000530623 Bovine viral diarrhea virus 2 Species 0.000 claims description 8
- 230000002085 persistent effect Effects 0.000 claims description 6
- 241001147662 Neospora caninum Species 0.000 claims description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 5
- 229930182490 saponin Natural products 0.000 claims description 5
- 150000007949 saponins Chemical class 0.000 claims description 5
- 241000606831 Histophilus somni Species 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 244000309465 heifer Species 0.000 claims description 3
- 244000309464 bull Species 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 241000712003 Human respirovirus 3 Species 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 5
- 241001293415 Mannheimia Species 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 41
- 229940001442 combination vaccine Drugs 0.000 abstract description 28
- 230000036961 partial effect Effects 0.000 abstract description 4
- 241001518163 Leptospira interrogans serovar Hardjo-bovis Species 0.000 abstract description 2
- 238000002955 isolation Methods 0.000 description 59
- 210000001519 tissue Anatomy 0.000 description 42
- 238000012360 testing method Methods 0.000 description 35
- 229940068196 placebo Drugs 0.000 description 33
- 239000000902 placebo Substances 0.000 description 33
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 238000007918 intramuscular administration Methods 0.000 description 22
- 210000003754 fetus Anatomy 0.000 description 20
- 210000004381 amniotic fluid Anatomy 0.000 description 19
- 230000035935 pregnancy Effects 0.000 description 19
- 210000003734 kidney Anatomy 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- 206010058874 Viraemia Diseases 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 14
- 238000003364 immunohistochemistry Methods 0.000 description 14
- 238000009395 breeding Methods 0.000 description 12
- 230000001488 breeding effect Effects 0.000 description 12
- 206010024238 Leptospirosis Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 230000001332 colony forming effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 5
- 238000003975 animal breeding Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- -1 coatings Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000000474 nursing effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 208000000995 spontaneous abortion Diseases 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 4
- 244000068687 Amelanchier alnifolia Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000589926 Leptospira interrogans serovar Hardjo Species 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000003736 gastrointestinal content Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010051226 Campylobacter infection Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001293418 Mannheimia haemolytica Species 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000710778 Pestivirus Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229940024545 aluminum hydroxide Drugs 0.000 description 3
- 238000002669 amniocentesis Methods 0.000 description 3
- 201000004927 campylobacteriosis Diseases 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012770 revaccination Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 2
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102100022477 DNA repair protein complementing XP-C cells Human genes 0.000 description 2
- 101000984570 Enterobacteria phage T4 Baseplate wedge protein gp53 Proteins 0.000 description 2
- 101000997743 Escherichia phage Mu Serine recombinase gin Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000618535 Homo sapiens DNA repair protein complementing XP-C cells Proteins 0.000 description 2
- 101000640924 Homo sapiens SEC23-interacting protein Proteins 0.000 description 2
- 241000031168 Leptospira borgpetersenii serovar Hardjo Species 0.000 description 2
- 101001099926 Mus musculus Ankycorbin Proteins 0.000 description 2
- 101000618540 Mus musculus DNA repair protein complementing XP-C cells homolog Proteins 0.000 description 2
- 241001138504 Mycoplasma bovis Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 206010047400 Vibrio infections Diseases 0.000 description 2
- 206010051511 Viral diarrhoea Diseases 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 102100039414 WD repeat-containing protein 48 Human genes 0.000 description 2
- 210000002718 aborted fetus Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 229940090213 lutalyse Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000017443 reproductive system disease Diseases 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000070928 Calligonum comosum Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000001726 Classical Swine Fever Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 206010061043 Clostridial infection Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241001137307 Cyprinodon variegatus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024234 Leptospira infections Diseases 0.000 description 1
- 241001215120 Leptospirales Species 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 229940124679 RSV vaccine Drugs 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- MZZINWWGSYUHGU-UHFFFAOYSA-J ToTo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 MZZINWWGSYUHGU-UHFFFAOYSA-J 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 208000008921 border disease Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/28011—Hepeviridae
- C12N2770/28022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40596902P | 2002-08-26 | 2002-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12915A true OA12915A (en) | 2006-10-13 |
Family
ID=31946951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200500058A OA12915A (en) | 2002-08-26 | 2003-08-14 | Vaccine for respiratory and reproductive system infections in cattle. |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20040081666A1 (me) |
| EP (2) | EP1536830A1 (me) |
| JP (4) | JP2006501237A (me) |
| KR (2) | KR20060116037A (me) |
| CN (1) | CN1315534C (me) |
| AP (1) | AP2005003238A0 (me) |
| AR (1) | AR041047A1 (me) |
| AT (1) | ATE533506T1 (me) |
| AU (2) | AU2003263390B2 (me) |
| BR (1) | BR0313806A (me) |
| CA (1) | CA2496750C (me) |
| EA (1) | EA011578B1 (me) |
| GT (1) | GT200300180A (me) |
| HK (1) | HK1078457A1 (me) |
| HR (2) | HRP20050192B1 (me) |
| IS (1) | IS7672A (me) |
| MA (1) | MA27388A1 (me) |
| ME (1) | ME00810B (me) |
| MX (1) | MXPA05002255A (me) |
| NO (1) | NO20050603L (me) |
| NZ (2) | NZ538394A (me) |
| OA (1) | OA12915A (me) |
| PA (1) | PA8581101A1 (me) |
| PE (1) | PE20040420A1 (me) |
| PL (1) | PL216541B1 (me) |
| RS (1) | RS20050177A (me) |
| TN (1) | TNSN05059A1 (me) |
| TW (1) | TWI272105B (me) |
| UA (1) | UA94689C2 (me) |
| UY (1) | UY27948A1 (me) |
| WO (1) | WO2004017990A1 (me) |
| ZA (1) | ZA200501171B (me) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179473B2 (en) | 1998-06-05 | 2007-02-20 | Boehringer Ingelheim Vetmedica Gmbh | Attenuated pestiviruses |
| US7135561B2 (en) | 2001-09-06 | 2006-11-14 | Boehringer Ingelheim Vetmedica Gmbh | Infectious bovine viral diarrhea virus clone |
| ME00810B (me) * | 2002-08-26 | 2012-03-20 | Zoetis Services Llc | Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke |
| US20050089533A1 (en) * | 2003-01-29 | 2005-04-28 | Joseph Frantz | Canine vaccines against Bordetella bronchiseptica |
| US7563449B2 (en) * | 2003-04-21 | 2009-07-21 | Pfizer Inc, | Methods for reducing cattle reproductive diseases |
| US7361357B2 (en) * | 2003-07-29 | 2008-04-22 | Pfizer Inc. | Safe mutant viral vaccines |
| AU2004299057B2 (en) * | 2003-12-17 | 2010-06-24 | Wyeth Llc | Methods for porducing storage stable viruses and immunogenic compositions thereof |
| ES2409782T3 (es) * | 2004-04-05 | 2013-06-27 | Zoetis P Llc | Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna |
| US7572455B2 (en) * | 2004-05-19 | 2009-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine comprising an attenuated pestivirus |
| UY29915A1 (es) * | 2005-11-15 | 2007-06-29 | Boehringer Ingelheim Vetmed | Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina |
| BRPI0716548B1 (pt) | 2006-09-11 | 2020-10-06 | Zoetis Services Llc | Vacina em emulsão, seu método de produção e método para preparação de uma bacterina leptospira tratada termicamente da vacina em emulsão |
| WO2008036747A2 (en) * | 2006-09-21 | 2008-03-27 | Amarillo Biosciences, Inc. | Composition and method for immunomodulation |
| US7803527B2 (en) * | 2007-10-31 | 2010-09-28 | Novartis Ag | Inactivated bovine herpes virus-1 and methods |
| NZ585877A (en) * | 2007-12-21 | 2012-06-29 | Pfizer | Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins |
| UY31930A (es) * | 2008-06-25 | 2010-01-29 | Boheringer Ingelheim Pharma Kg | Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante |
| CN102238961A (zh) | 2008-10-03 | 2011-11-09 | 诺华公司 | 牛疱疹病毒1型组合物,疫苗及方法 |
| US8846054B2 (en) * | 2009-01-09 | 2014-09-30 | Boehringer Ingelheim Vetmedica, Inc. | Method of treating pregnant cows and/or heifers |
| US9364527B2 (en) * | 2011-06-10 | 2016-06-14 | Novartis Tiergesundheit Ag | Bovine vaccines and methods |
| RU2522780C2 (ru) * | 2012-07-27 | 2014-07-20 | Государственное научное учреждение Всероссийский научно-исследовательский институт ветеринарной санитарии, гигиены и экологии Российской академии сельскохозяйственных наук | Способ получения вакцины против инфекционного ринотрахеита крупного рогатого скота |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| US20140147475A1 (en) | 2012-11-29 | 2014-05-29 | Antonius Arnoldus Christiaan Jacobs | Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida |
| US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
| EP2976102B1 (en) | 2013-03-18 | 2019-12-11 | Intervet International B.V. | Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
| TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
| EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
| US11013798B2 (en) | 2016-03-21 | 2021-05-25 | South Dakota Board Of Regents | Orf virus-based platform for vaccine delivery |
| JP2019533995A (ja) | 2016-10-05 | 2019-11-28 | ゾエティス・サービシーズ・エルエルシー | 強力な生ワクチンとして使用するための安定に脱水された原生動物を提供する凍結乾燥方法 |
| RU2643335C1 (ru) * | 2016-11-14 | 2018-01-31 | Федеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургская государственная академия ветеринарной медицины (ФГБОУ ВПО СПбГ АВМ) | Инактивированная бивалентная гидроокись алюминиевая вакцина против кампилобактериоза собак |
| GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
| CN110317749B (zh) * | 2019-06-19 | 2021-01-22 | 山东省农业科学院奶牛研究中心 | 一株牛支原体强毒株及其应用 |
| RU2764220C1 (ru) * | 2020-12-02 | 2022-01-14 | Федеральное государственное бюджетное научное учреждение "Краснодарский научный центр по зоотехнии и ветеринарии" ФГБНУ КНЦЗВ | Способ предупреждения риска заболевания парагриппом-3 у телят |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3634587A (en) * | 1969-11-06 | 1972-01-11 | Ralston Purina Co | Method of immunizing cattle against bovine respiratory disease syndrome |
| BE759425A (fr) * | 1969-11-28 | 1971-05-25 | Mebus Charles A | Vaccins contre la diarrhee du veau, leur preparation et emploi |
| US5593873A (en) | 1986-01-27 | 1997-01-14 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus |
| US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
| EP0273512B1 (en) | 1986-12-19 | 1991-02-27 | Duphar International Research B.V | Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide |
| US6291228B1 (en) * | 1988-08-03 | 2001-09-18 | Vericore Limited | Vaccine |
| GB8818415D0 (en) * | 1988-08-03 | 1988-09-07 | Animal Health Inst | Vaccine |
| MX9301736A (es) | 1992-03-30 | 1994-01-31 | Smithkline Beecham Corp | Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1. |
| US5951988A (en) * | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
| NZ276234A (en) | 1993-11-05 | 1998-01-26 | Bayer Ag Substituted Under Sec | An attenuated replicating non pathogenic flavivirus (bovine viral diarrhoea virus - bvdv) vaccine |
| PT1820512E (pt) * | 1994-05-10 | 2013-10-09 | Boehringer Ingelheim Vetmed | Vacina viva modificada melhorada contra brsv |
| US5709865A (en) | 1994-11-10 | 1998-01-20 | Biostar Inc. | Immunogenic composition against Bovine Viral Diarrhea Virus II glycoprotein 53 (BVDV-II gp53) |
| US6001613A (en) | 1996-05-24 | 1999-12-14 | Board Of Regents Of University Of Nebraska | Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid |
| US6060457A (en) | 1996-06-20 | 2000-05-09 | Universite De Montreal | DNA plasmid vaccine for immunization of animals against BVDV |
| BR9803232A (pt) * | 1997-08-26 | 2000-01-11 | Pfizer Prod Inc | Vaicna de neospora. |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| UA78180C2 (uk) * | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| EP0924295A3 (en) * | 1997-12-04 | 2001-05-16 | Pfizer Products Inc. | DNA encoding neospora dihydrofolate reductase-thymidylate synthase |
| AU3757199A (en) | 1998-04-24 | 1999-11-16 | Washington University | Chimeras of hepatitis c virus and bovine viral diarrhea virus |
| AU769539B2 (en) * | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
| ME00810B (me) * | 2002-08-26 | 2012-03-20 | Zoetis Services Llc | Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke |
| JP5179521B2 (ja) | 2007-03-05 | 2013-04-10 | カディラ・ヘルスケア・リミテッド | ペグ‐インターフェロンアルファ接合体および凍結保護剤としてラフィノースを含む組成物 |
-
2003
- 2003-08-14 ME MEP-2009-213A patent/ME00810B/me unknown
- 2003-08-14 AP AP2005003238A patent/AP2005003238A0/xx unknown
- 2003-08-14 KR KR1020067022893A patent/KR20060116037A/ko active Search and Examination
- 2003-08-14 AT AT06122758T patent/ATE533506T1/de active
- 2003-08-14 RS YUP-2005/0177A patent/RS20050177A/sr unknown
- 2003-08-14 JP JP2004530459A patent/JP2006501237A/ja active Pending
- 2003-08-14 UA UAA200501771A patent/UA94689C2/ru unknown
- 2003-08-14 CN CNB038203162A patent/CN1315534C/zh not_active Expired - Lifetime
- 2003-08-14 CA CA2496750A patent/CA2496750C/en not_active Expired - Lifetime
- 2003-08-14 NZ NZ538394A patent/NZ538394A/en not_active IP Right Cessation
- 2003-08-14 AU AU2003263390A patent/AU2003263390B2/en not_active Expired
- 2003-08-14 OA OA1200500058A patent/OA12915A/en unknown
- 2003-08-14 KR KR1020057003230A patent/KR20050062542A/ko active Search and Examination
- 2003-08-14 EP EP03792580A patent/EP1536830A1/en not_active Ceased
- 2003-08-14 MX MXPA05002255A patent/MXPA05002255A/es active IP Right Grant
- 2003-08-14 NZ NZ565206A patent/NZ565206A/en not_active IP Right Cessation
- 2003-08-14 EA EA200500275A patent/EA011578B1/ru not_active IP Right Cessation
- 2003-08-14 EP EP06122758A patent/EP1743652B1/en not_active Expired - Lifetime
- 2003-08-14 BR BR0313806-2A patent/BR0313806A/pt not_active Application Discontinuation
- 2003-08-14 WO PCT/IB2003/003633 patent/WO2004017990A1/en active Application Filing
- 2003-08-14 PL PL375548A patent/PL216541B1/pl unknown
- 2003-08-20 TW TW092122872A patent/TWI272105B/zh not_active IP Right Cessation
- 2003-08-22 UY UY27948A patent/UY27948A1/es not_active Application Discontinuation
- 2003-08-22 PE PE2003000857A patent/PE20040420A1/es not_active Application Discontinuation
- 2003-08-25 AR ARP030103054A patent/AR041047A1/es unknown
- 2003-08-25 PA PA20038581101A patent/PA8581101A1/es unknown
- 2003-08-25 GT GT200300180A patent/GT200300180A/es unknown
- 2003-08-26 US US10/647,919 patent/US20040081666A1/en not_active Abandoned
-
2005
- 2005-01-27 IS IS7672A patent/IS7672A/is unknown
- 2005-02-03 NO NO20050603A patent/NO20050603L/no not_active Application Discontinuation
- 2005-02-09 ZA ZA200501171A patent/ZA200501171B/en unknown
- 2005-02-25 TN TNP2005000059A patent/TNSN05059A1/fr unknown
- 2005-02-25 MA MA28121A patent/MA27388A1/fr unknown
- 2005-02-28 HR HRP20050192AA patent/HRP20050192B1/hr not_active IP Right Cessation
- 2005-11-18 HK HK05110344A patent/HK1078457A1/xx not_active IP Right Cessation
-
2007
- 2007-08-30 US US11/897,421 patent/US20070298053A1/en not_active Abandoned
-
2008
- 2008-12-16 AU AU2008258154A patent/AU2008258154B2/en not_active Expired
-
2009
- 2009-05-14 HR HR20090271A patent/HRP20090271A2/xx not_active Application Discontinuation
- 2009-05-15 JP JP2009118662A patent/JP2009215309A/ja not_active Withdrawn
-
2010
- 2010-06-22 US US12/820,566 patent/US9662384B2/en active Active
-
2011
- 2011-12-16 JP JP2011275303A patent/JP5785073B2/ja not_active Expired - Lifetime
-
2012
- 2012-12-28 US US13/729,206 patent/US20130129779A1/en not_active Abandoned
-
2015
- 2015-06-03 JP JP2015113008A patent/JP2015172069A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9662384B2 (en) | Cattle reproductive disease vaccines | |
| US20070172877A1 (en) | Methods for preventing cattle reproductive diseases | |
| EP1727562B1 (en) | Method of vaccination against testicular bvdv infection | |
| MXPA06010631A (en) | Method of vaccination against testicular bvdv infection |